Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Not admitted · Not a forecast

Rules 1.1.0 · as of 14 Sep 2026

Owen Scott Muir · Said 24 Jun 2023 · owen-0558

Quote

Not a forecast

“The most critical issue, at least to my eye, from a scalability perspective, is that for the clinical trials, the FDA is—in draft guidance— leaning both having two monitors”
· I'm a Psychic...About Timing of Articles Related to Open Comment Periods Related to Psychedelics. · substack post Paid

The author reads the FDA's June 2023 draft guidance on psychedelic drug development. He singles out the requirement of two monitors per treatment session (a lead monitor with an independent clinical license plus an assistant) as the main scalability problem for future psychedelic clinical trials.

Descriptive, retrospective, or a statement of preference; no future state asserted.

← Earlier · Later → · All statements